LAUSR

abdominal sarcopenia. Among chronic aortic disease patients, thoracic and abdominal sarcopenia occurred in 37% and 35% (81% agreement). Sarcopenic patients were older, had lower body mass indices, and were more frequently male and white; comorbidities and procedural characteristics were similar between patient groups. Whereas abdominal sarcopenia did not predict mortality at any time point (Fig 1; 2-year mortality, 16% vs 15%; P 1⁄4 .66), T12 sarcopenia was associated with substantially higher long-term mortality (Fig 2; 2-year mortality 23% vs 10%; P < .05). In contrast, among injured patients, thoracic sarcopenia was less frequent (15%), and was not associated with increased mortality (0% vs 15%; P 1⁄4 .58). Conclusions: Thoracic sarcopenia is common among patients with chronic aortic disease, and is an important and specific predictor of long-term mortality after TEVAR. In contrast, psoas-derived assessment of sarcopenia may not be valid in this patient population. As an objective, reproducible, and patient-specific indicator of frailty, T12 sarcopenia may provide for valuable risk assessment to optimize appropriate patient selection for TEVAR and to identify patients at greater risk for late adverse outcomes.